These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1221 related items for PubMed ID: 29950407

  • 1. Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    Davido DJ, Tu EM, Wang H, Korom M, Gazquez Casals A, Reddy PJ, Mostafa HH, Combs B, Haenchen SD, Morrison LA.
    J Virol; 2018 Sep 01; 92(17):. PubMed ID: 29950407
    [Abstract] [Full Text] [Related]

  • 2. Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation.
    Mostafa HH, Thompson TW, Konen AJ, Haenchen SD, Hilliard JG, Macdonald SJ, Morrison LA, Davido DJ.
    J Virol; 2018 Apr 01; 92(7):. PubMed ID: 29321311
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of an HSV-1 Neuro-Attenuated Vaccine in Mice Is Reduced by Preventing Viral DNA Replication.
    Wang H, Davido DJ, Mostafa HH, Morrison LA.
    Viruses; 2022 Apr 22; 14(5):. PubMed ID: 35632611
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.
    Keadle TL, Morrison LA, Morris JL, Pepose JS, Stuart PM.
    J Virol; 2002 Apr 22; 76(8):3615-25. PubMed ID: 11907201
    [Abstract] [Full Text] [Related]

  • 5. Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.
    Geiss BJ, Smith TJ, Leib DA, Morrison LA.
    J Virol; 2000 Dec 22; 74(23):11137-44. PubMed ID: 11070010
    [Abstract] [Full Text] [Related]

  • 6. Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection.
    Morrison LA, Knipe DM.
    J Virol; 1994 Feb 22; 68(2):689-96. PubMed ID: 8289372
    [Abstract] [Full Text] [Related]

  • 7. ICP0 is required for efficient reactivation of herpes simplex virus type 1 from neuronal latency.
    Halford WP, Schaffer PA.
    J Virol; 2001 Apr 22; 75(7):3240-9. PubMed ID: 11238850
    [Abstract] [Full Text] [Related]

  • 8. Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1.
    Morrison LA, Knipe DM.
    Virology; 1996 Jun 15; 220(2):402-13. PubMed ID: 8661391
    [Abstract] [Full Text] [Related]

  • 9. Role of CD8+ T cells and lymphoid dendritic cells in protection from ocular herpes simplex virus 1 challenge in immunized mice.
    Matundan H, Mott KR, Ghiasi H.
    J Virol; 2014 Jul 15; 88(14):8016-27. PubMed ID: 24807710
    [Abstract] [Full Text] [Related]

  • 10. The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.
    Augustinova H, Hoeller D, Yao F.
    J Virol; 2004 Jun 15; 78(11):5756-65. PubMed ID: 15140973
    [Abstract] [Full Text] [Related]

  • 11. Herpes simplex virus virion host shutoff (vhs) activity alters periocular disease in mice.
    Smith TJ, Ackland-Berglund CE, Leib DA.
    J Virol; 2000 Apr 15; 74(8):3598-604. PubMed ID: 10729135
    [Abstract] [Full Text] [Related]

  • 12. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge.
    Osorio Y, Ghiasi H.
    J Virol; 2005 Mar 15; 79(6):3297-308. PubMed ID: 15731224
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo.
    Halford WP, Schaffer PA.
    J Virol; 2000 Jul 15; 74(13):5957-67. PubMed ID: 10846077
    [Abstract] [Full Text] [Related]

  • 15. Mutations Inactivating Herpes Simplex Virus 1 MicroRNA miR-H2 Do Not Detectably Increase ICP0 Gene Expression in Infected Cultured Cells or Mouse Trigeminal Ganglia.
    Pan D, Pesola JM, Li G, McCarron S, Coen DM.
    J Virol; 2017 Jan 15; 91(2):. PubMed ID: 27847363
    [Abstract] [Full Text] [Related]

  • 16. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease.
    van Lint AL, Torres-Lopez E, Knipe DM.
    Virology; 2007 Nov 25; 368(2):227-31. PubMed ID: 17915278
    [Abstract] [Full Text] [Related]

  • 17. An M2 Rather than a TH2 Response Contributes to Better Protection against Latency Reactivation following Ocular Infection of Naive Mice with a Recombinant Herpes Simplex Virus 1 Expressing Murine Interleukin-4.
    Lee DH, Ghiasi H.
    J Virol; 2018 May 15; 92(10):. PubMed ID: 29491152
    [Abstract] [Full Text] [Related]

  • 18. A Highly Efficacious Herpes Simplex Virus 1 Vaccine Blocks Viral Pathogenesis and Prevents Corneal Immunopathology via Humoral Immunity.
    Royer DJ, Gurung HR, Jinkins JK, Geltz JJ, Wu JL, Halford WP, Carr DJJ.
    J Virol; 2016 Jun 01; 90(11):5514-5529. PubMed ID: 27030264
    [Abstract] [Full Text] [Related]

  • 19. A non-consensus branch point plays an important role in determining the stability of the 2-kb LAT intron during acute and latent infections of herpes simplex virus type-1.
    Mukerjee R, Kang W, Suri V, Fraser NW.
    Virology; 2004 Jul 01; 324(2):340-9. PubMed ID: 15207620
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.